Prelude Therapeutics News

Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)

TipRanksMay 8 06:07 ET

Buy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical Prospects

TipRanksMay 8 00:56 ET

Prelude Therapeutics Analyst Ratings

BenzingaMar 13 05:18 ET

Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)

TipRanksMar 13 00:30 ET

H.C. Wainwright Cuts Prelude Therapeutics to Neutral, Cites Valuation

Seeking AlphaFeb 21 17:29 ET

Prelude Therapeutics Analyst Ratings

BenzingaFeb 20 09:01 ET

Prelude Therapeutics Stock Downgraded to Neutral Amid Anticipation for Trial Results

InvestingFeb 20 07:08 ET

Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)

TipRanksFeb 16 06:59 ET

Morgan Stanley Downgrades Prelude Therapeutics to Underweight, Lowers Price Target to $4

BenzingaDec 19, 2023 09:33 ET

Prelude Therapeutics Analyst Ratings

BenzingaDec 19, 2023 09:31 ET

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $5

BenzingaNov 7, 2023 13:20 ET

Prelude Therapeutics Analyst Ratings

BenzingaNov 7, 2023 13:19 ET

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $6

BenzingaOct 19, 2023 07:06 ET

Prelude Therapeutics Analyst Ratings

BenzingaOct 19, 2023 07:04 ET

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $17 Price Target

BenzingaAug 17, 2023 06:32 ET

Prelude Therapeutics Analyst Ratings

BenzingaAug 17, 2023 06:31 ET

H.C. Wainwright Sticks to Its Buy Rating for Prelude Therapeutics (PRLD)

TipRanksAug 17, 2023 06:25 ET

Morgan Stanley Reiterates Equal-Weight on Prelude Therapeutics, Maintains $10 Price Target

BenzingaAug 4, 2023 14:46 ET

Prelude Therapeutics Analyst Ratings

BenzingaAug 4, 2023 14:45 ET

Barclays Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $5

BenzingaAug 4, 2023 07:09 ET